Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

Summary by Hastings Tribune
BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 clinical trial of ATH-1105…

1 Articles

Hastings TribuneHastings Tribune
Center

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 clinical trial of ATH-1105…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Thursday, August 14, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Bothell icon

Bothell

News
For You
SearchBlindspotLocal